German Merck watches evobrutinib’s benefit melt away
Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
Asco 2019 – KRAS chase heats up with Amgen data
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Time to restock big pharma’s leaking pipeline
The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Go or no go? Novartis, Sanofi and Regeneron await US verdicts
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Alnylam swaps Regeneron for Sanofi
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.